{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:51Z","timestamp":1792273551683,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00198-026-08177-1","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:58:50Z","timestamp":1786460330000},"page":"2133-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Romosozumab in older adults: real-world patterns in fracture liaison service cohort"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-4402","authenticated-orcid":false,"given":"Bernardo A.","family":"Cedeno-Veloz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba M. Rodr\u00edguez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Casaj\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Guruceaga-Eguillor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ruiz-Izquieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoya","family":"Zazpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Mart\u00ednez-Velilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"8177_CR1","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","volume":"2","author":"A-M Wu","year":"2021","unstructured":"Wu A-M, Bisignano C, James SL et al (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev 2:e580\u2013e592. https:\/\/doi.org\/10.1016\/S2666-7568(21)00172-0","journal-title":"Lancet Healthy Longev"},{"key":"8177_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40520-025-02973-1","volume":"37","author":"C Panait","year":"2025","unstructured":"Panait C, D\u2019Amelio P (2025) Advancing care: optimizing osteoporosis treatment in the older and oldest old population. Aging Clin Exp Res 37:123. https:\/\/doi.org\/10.1007\/s40520-025-02973-1","journal-title":"Aging Clin Exp Res"},{"key":"8177_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40744-024-00743-5","volume":"12","author":"A Sicras-Mainar","year":"2025","unstructured":"Sicras-Mainar A, Sorio-Vilela F, Sacrest-Soy M et al (2025) Real-world osteoporosis treatment gap and costs in Spain: data from women with a first fragility fracture or diagnosis of postmenopausal osteoporosis. Rheumatol Ther 12:315\u2013335. https:\/\/doi.org\/10.1007\/s40744-024-00743-5","journal-title":"Rheumatol Ther"},{"key":"8177_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00198-023-06827-2","volume":"34","author":"RJ Moon","year":"2023","unstructured":"Moon RJ, Reginster J-Y, Al-Daghri NM et al (2023) Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporos Int 34:1283\u20131299. https:\/\/doi.org\/10.1007\/s00198-023-06827-2","journal-title":"Osteoporos Int"},{"key":"8177_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10538","volume":"5","author":"JG Sfeir","year":"2021","unstructured":"Sfeir JG, Pignolo RJ (2021) Pharmacologic interventions for fracture risk reduction in the oldest old: what is the evidence? JBMR Plus 5:e10538. https:\/\/doi.org\/10.1002\/jbm4.10538","journal-title":"JBMR Plus"},{"key":"8177_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70142","author":"H Maruyama","year":"2025","unstructured":"Maruyama H, Iwasa E, Watanabe S et al (2025) Cardiovascular risk of romosozumab vs. teriparatide: a cohort study using Japan\u2019s national claims database. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.70142","journal-title":"Clin Pharmacol Ther"},{"key":"8177_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","volume":"48","author":"S-H Cheng","year":"2025","unstructured":"Cheng S-H, Chu W, Chou W-H et al (2025) Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Drug Saf 48:7\u201323. https:\/\/doi.org\/10.1007\/s40264-024-01475-9","journal-title":"Drug Saf"},{"key":"8177_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95685","author":"R Neupane","year":"2025","unstructured":"Neupane R, Ness B, Sivakumar B et al (2025) The impact of fracture liaison services on outcomes in older patients: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.95685","journal-title":"Cureus"},{"key":"8177_CR9","unstructured":"The jamovi project (2026) jamovi (Version 2.7) [Computer Software]. https:\/\/www.jamovi.org"},{"key":"8177_CR10","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1210\/clinem\/dgae484","volume":"110","author":"MC Hartz","year":"2025","unstructured":"Hartz MC, Johannessen FB, Harsl\u00f8f T, Langdahl BL (2025) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 110:e1640\u2013e1652. https:\/\/doi.org\/10.1210\/clinem\/dgae484","journal-title":"J Clin Endocrinol Metab"},{"key":"8177_CR11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42115","author":"MM Alahmari","year":"2023","unstructured":"Alahmari MM, AlHilali AI, Thabet TA et al (2023) Impact of medication adherence on bone mineral density and fracture risk in patients with osteoporosis: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.42115","journal-title":"Cureus"},{"key":"8177_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4321\/S1889-836X2022000100002","volume":"14","author":"J Riancho","year":"2022","unstructured":"Riancho J, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n J (2022) Resumen ejecutivo de las Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis postmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022). Rev Osteoporos Metab Miner 14:5\u201312. https:\/\/doi.org\/10.4321\/S1889-836X2022000100002","journal-title":"Rev Osteoporos Metab Miner"},{"key":"8177_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010097","author":"BA Cedeno-Veloz","year":"2023","unstructured":"Cedeno-Veloz BA, Casadamon-Munarriz I, Rodr\u00edguez-Garc\u00eda A et al (2023) Effect of a multicomponent intervention with tele-rehabilitation and the Vivifrail\u00a9 exercise programme on functional capacity after hip fracture: study protocol for the ActiveFLS randomized controlled trial. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13010097","journal-title":"J Clin Med"},{"key":"8177_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf164","author":"MR McClung","year":"2025","unstructured":"McClung MR (2025) Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease. J Bone Miner Res. https:\/\/doi.org\/10.1093\/jbmr\/zjaf164","journal-title":"J Bone Miner Res"},{"key":"8177_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08177-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:07:21Z","timestamp":1792271241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08177-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8177"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08177-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study followed the principles of the Declaration of Helsinki and was approved by the Navarra Research Ethics Committee (PI_2022\/2), Spain. Written informed consent was obtained from each patient for publication of this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cedeno-Veloz has received grant support, advisory board honoraria, consultancy fees, and\/or speaker fees from Theramex, UCB, Amgen, Gedeon, FAES. The rest of the authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI and AI-assisted technologies An AI language model (ChatGPT, GPT-5.2; OpenAI, San Francisco, CA; accessed 1 January 2026) was used solely to improve the fluency and grammar of the manuscript. The authors reviewed and edited all AI-generated suggestions and accepted full responsibility for the final content.","order":3,"name":"Ethics","label":"AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}